Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CHOP + Bortezomib in Newly Diagnosed Mantle Cell Lymphoma
NCT00376961Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Aug 2006
- Primary completion
- Dec 2012
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in mantle cell lymphoma (MCL), sponsored by SWOG Cancer Research Network. Primary endpoint: 2-year Progression-free Survival. Started Aug 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00376961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00376961.